Melanoma Pipeline Review, H1 2018 - Therapeutic Assessment of 250 Companies & Drug Profiles - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--Sep 28, 2018--The “Melanoma - Pipeline Review, H1 2018” drug pipelines has been added to ResearchAndMarkets.com’s offering.
Melanoma - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Melanoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Melanoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Melanoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 3, 1, 19, 116, 125, 1, 9, 217, 30 and 3 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages comprises 2, 18, 13, 1, 73 and 10 molecules, respectively.
Melanoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Key Topics Covered:Introduction Melanoma - Overview Melanoma - Therapeutics Development Melanoma - Therapeutics Assessment Melanoma - Companies Involved in Therapeutics Development Melanoma - Drug Profiles Melanoma - Dormant Projects Melanoma - Discontinued Products Melanoma - Product Development Milestones Appendix
For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/8zcmcr/melanoma_pipeline?w=4
View source version on businesswire.com:https://www.businesswire.com/news/home/20180928005643/en/
Laura Wood, Senior Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics:Skin Cancer Drugs
INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL
SOURCE: Research and Markets
Copyright Business Wire 2018.
PUB: 09/28/2018 05:31 PM/DISC: 09/28/2018 05:31 PM